Pancreatic Cancer Surgeons
Shanghai's top pancreatic cancer surgeons — high volume, internationally trained, pioneering robotic and minimally invasive techniques.
Fudan University Shanghai Cancer Center
复旦大学附属肿瘤医院
Dr. Xiaowu Xu
徐晓武
Chief Physician · PhD Supervisor · Director, Minimally Invasive Pancreatic Surgery Center
Trained under Prof. Mou Yiping, one of China's most influential minimally invasive surgery pioneers. In 2018, recruited to Fudan Cancer Center to build the Minimally Invasive Pancreatic Surgery Center from scratch. His team was among the first in China to routinely perform laparoscopic Whipple procedures with live national conference broadcasts. Pioneer in function-preserving surgery: spleen-preserving distal pancreatectomy, pancreatic enucleation, duodenum-preserving pancreatic head resection, and middle pancreatectomy. 20+ SCI papers, 3 NSFC grants. In Dec 2024, Prof. Martin Loos from Heidelberg University Hospital observed Dr. Xu's robotic and laparoscopic Whipple procedures and rated them as world-class.
Dr. Chen Liu
刘辰
Chief Physician · PhD Supervisor · Deputy Director, Pancreatic Surgery
Trained under Prof. Ni Quanxing (倪泉兴) — one of China's foundational pancreatic surgeons. 2015 International Association of Pancreatology (IAP) Outstanding Surgical Video Award — selected from among the best surgical videos submitted globally, peer-reviewed by an international panel. Innovator of the "middle approach" laparoscopic Whipple ("Leave the Vein Alone" concept). Live surgery demonstrator at the 36th Italian Digestive Surgery Congress (Milan, 2025) — European peers called it "textbook level." Published on laparoscopic Whipple with portal vein/superior mesenteric vein resection and reconstruction (PMID: 36690522). Editorial board member, Hepatobiliary and Pancreatic Diseases International.
Dr. Jin Xu
徐近
Pancreatic Surgery · Fudan University Shanghai Cancer Center
ASCO 2025 co-reviewer with Dr. Wei Miaoyan — selected 3 landmark pancreatic cancer precision medicine studies for expert commentary. Contributor to mitochondria DNA mutation research in pancreatic cancer (PMID: 41639740). Active in ctDNA-guided adjuvant therapy research.
Ruijin Hospital
上海交通大学医学院附属瑞金医院
Dr. Jiabin Jin
金佳斌
Chief Physician · Postdoctoral Supervisor · Director, Pancreatic Surgery Ward 2 · VP, Ruijin Hainan Campus
International training at Paul Brousse Hospital (Paris) hepatobiliary center, Strasbourg Civil Hospital digestive oncology, and Johns Hopkins Hospital research fellowship. Author of JAMA Surgery landmark 10-year study comparing 450 robotic vs 634 open Whipple procedures. Pioneer in robotic spleen-preserving distal pancreatectomy (PMID in Int J Med Robotics). Also performs robotic pancreatic enucleation and R-RAMPS procedures. Successfully operated on a 10-year-old Canadian girl with solid pseudopapillary neoplasm — robotic spleen-preserving surgery, 3-day mobilization, ~$22,000 total cost. Google Scholar: profile →
Zhongshan Hospital
复旦大学附属中山医院
Dr. Liang Liu
刘亮
Chief Physician · Professor · "Surgery + Oncology" Dual PhD Supervisor · Director, Pancreatic Surgery · Deputy Director, General Surgery
One of Shanghai's most experienced pancreatic cancer surgeons. Holds a rare dual doctoral degree in Surgery and Oncology — uniquely positioned to design integrated surgical + systemic treatment strategies. 1,500+ pancreatic cancer surgeries personally completed, 10,000+ cases managed through integrated care. Key specialist in conversion therapy for locally advanced pancreatic cancer — turning inoperable tumors into operable ones through neoadjuvant treatment. Published in Journal for Immunotherapy of Cancer (JITC, 2024) on CD161 as a novel immune checkpoint target. Co-author of the 2012 China Pancreatic Cancer Clinical Diagnosis and Treatment Guidelines. Multi-center proteogenomic study on 873 surgical specimens (PMID: 41556438, Advanced Science 2026).
Changhai Hospital
海军军医大学附属长海医院
Dr. Gang Jin
金刚
Chief Physician · Professor · PhD Supervisor · Director, Pancreatic-Hepatobiliary-Splenic Surgery · Vice Director, Shanghai Pancreatic Disease Research Institute
Known as the "Diamond Drill" (钻石钻) — the surgeon capable of cracking the hardest cases in abdominal surgery. Led the team that published the world's first KRAS G12V-targeted TCR-T cell gene therapy Phase I/II trial for recurrent pancreatic cancer (Molecular Therapy, 2026, PMID: 41814655). Published 103 consecutive robotic pancreatic enucleation procedures — one of the largest single-institution series. Pioneer in neoadjuvant conversion therapy and "textbook outcome" quality metrics. Military-affiliated hospital with fast-track decision-making and structured multidisciplinary team meetings.
Shanghai First People's Hospital
上海市第一人民医院
Dr. Jiang Long
龙江
Chief Physician · Professor · PhD Supervisor · Director, Hepatobiliary Surgery · Assistant Director, Shanghai Pancreatic Tumor Research Institute
Trained under Prof. Ni Quanxing — same mentor lineage as Dr. Liu Chen. Unique combination of surgical + arterial interventional skills — performs 400+ interventional procedures annually alongside surgical caseload. 30+ SCI papers, 4 national invention patents. Executive Secretary-General of Shanghai Anti-Cancer Association. Strong focus on pancreatic neuroendocrine tumors (PNETs). At Shanghai First People's Hospital, international department pricing is 15–30% lower than top-tier hospitals while maintaining comparable surgical quality. A more accessible option for international patients.
Disclaimer: Doctor profiles are based on publicly available information from hospital websites, published literature, and professional society records. MedInSh is not affiliated with any hospital or physician. All information is subject to change — verify directly with the hospital's international department before making treatment decisions. This website does not constitute medical advice.